ArticleOman medical journal2025
Long-Term Humoral Response to Hepatitis B Vaccination in Patients with Inflammatory Bowel Disease in Oman: Impact of Prednisolone and Esomeprazole as Contributing Factors.
Article in Oman medical journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Inflammatory bowel disease (IBD) is a global health concern with increasing incidence. Many patients with IBD have impaired immunity, leading to suboptimal response to vaccines. Hepatitis B Virus (HBV) vaccination has been part of compulsory childhood immunization program since 1990 in Oman. Given the concerns about vaccine immunogenicity in patients with IBD, we designed this study to quantify the immune response to scheduled HBV vaccination in Omani patients with IBD and compare it with that in a matching control cohort of healthy Omani blood donors. Methods: This retrospective case-control study was conducted from 1 January to 31 May 2024, at Sultan Qaboos University Hospital. We enrolled a total of 252 participants: 126 patients with IBD and 126 controls. Baseline demographics, comorbidities, and viral serologies before and after vaccination were collected. The primary outcome was long term immune response to HBV vaccination. Secondary outcomes included identifying factors associated with suboptimal vaccine response. Results: Durable protective immune response to HBV vaccine was achieved in 29 (23.0%) patients with IBD and 109 (86.5%) controls. Prednisolone and esomeprazole therapies were both significantly associated with suboptimal vaccine response ( Conclusions: Omani patients with IBD show markedly reduced long-term immunogenicity to HBV vaccination. Esomeprazole and corticosteroid therapies may be associated with this diminished response. These findings highlight the importance of reassessing the immunogenicity to HBV vaccination, and potentially other protective vaccinations, in all patients with IBD as part of their standard of care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.